Inhibitory effect of a synthetic prostacyclin analogue, Beraprost, on urokinase-type plasminogen activator expression in RC-K8 human lymphoma cells

Thrombosis and Haemostasis

Volumn 75, Issue 6, 1996, Pages 928-932

  Nomura, Naoki ^a   Niiya, Kenji ^a   Shinbo, Masahiro ^a   Ozawa, Tetsuo ^a   Hayakawa, Yumiko ^a   Higashiyama, Ko Ichi ^a   Fujimaki, Masao ^a   Sakuragawa, Nobuo ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; CYCLIC AMP DEPENDENT PROTEIN KINASE; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTACYCLIN DERIVATIVE; UROKINASE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE REPRESSION; HUMAN; HUMAN CELL; LYMPHOMA CELL; NORTHERN BLOTTING; PRIORITY JOURNAL;

EID: 0029960406     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650396     Document Type: Article

References (38)

1. Roldan AL, Cubellis MV, Masucei MT, Behrendt N, Lund LR, Danø K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis [published erratum appears in EMBO J 1990 May; 9 (5): 1674]. EMBO J 1990; 9: 467-74.
2. Ellis V, Pyke C, Eriksen J, Solberg H, Danß K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. [Review]. Ann NY Acad Sci 1992; 667: 13-31.
3. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993; 90: 5021-5.
4. Ganesh S, Sier C, Heerding MM, Griffioen G, Lamers C, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344: 401-2.
5. Wang H, Skibber J, Juarez J, Boyd D. Transcriptional activation of the urokinase receptor gene in invasive colon cancer. Int J Cancer 1994; 58: 650-7.
6. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54: 2900-7.
7. Wang SN, Miyauchi M, Koshikawa N, Maruyama K, Kubota T, Miura K, Kurosawa Y, Awaya A, Kanai Y. Antigen expression associated with lymph node metastasis in gastric adenocarcinomas. Pathology International 1994; 44: 844-9.
8. Duffy MJ, Reilly D, Mcdermott E, Ohiggins N, Fennelly JJ, Andreasen PA. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994; 74: 2276-80.
9. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dana K, Grondahlhansen J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-5.
10. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
11. Moncada S, Herman AG, Higgs EA, Vane JR. Differential formation of prostacyclin (PCX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 1977; 11: 323-44.
12. Moncada S, Korbut R, Bunting S, Vane JR. Prostacyclin is a circulating hormone. Nature 1978; 273: 767-8.
13. Armstrong JM, Dusting GJ, Moncada S, Vane JR. Cardiovascular actions of prostacydin (PGI2), a metabolite of arachidonic acid which is synthesized by blood vessels. Circ Res 1978; 43 (Supp. 1): 112-9.
14. Kadowitz PJ, Chapnick BM, Feigen LP, Hyman AL, Nelson PK, Spannhake EW. Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, PGI2. J Applied Physiol: Respiratory Environ Exercise Physiol 1978; 45: 408-13.
15. Honn KV, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenomenon. [Review], Semin Thromb Hemost 1992; 18: 392-415.
16. Schneider MR, Tang DO, Schirner M, Honn KV. Prostacydin and its analogues: antimetastatic effects and mechanisms of action. [Review]. Cancer Metastasis Rev 1994; 13: 349-64.
17. Niiya K, Nsimba M, Hayashi T, Sakuragawa N. Down-regulation of urokinase secretion from a human lymphoma cell line RC-K8 by dexamethasone without inducing plasminogen activator inhibitors. Thromb Res 1992; 65: 311-21.
18. Kubonishi I, Niiya K, Yamashita M, Yano S, Abe T, Ohtsuki Y, Miyoshi I. Characterization of a new human lymphoma cell line (RC-K8) with t(11; 14) chromosome abnormality. Cancer 1986; 58: 1453-60.
19. Shinbo M, Niiya K, Al-mokdad M, Hayakawa Y, Hiraga K, Fujimaki M, Sakuragawa N. Protein kinase activity-dependent inhibition of urokinase-type plasminogen activator gene transcription by cyclic AMP in human pre-B lymphoma cell line RC-K8. Biochim Biophys Acta 1995; 1268: 293-9.
20. Degen JL. Estensen RD, Nagamine Y, Reich E. Induction and desensitization of plasminogen activator gene expression by tumor promoters. J Biol Chem 1985; 260: 12426-33.
21. Canipari R, O'Connell ML, Meyer G, Strickland S. Mouse ovarian granulosa cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells produce tissue-type plasminogen activator. J Cell Biol 1987; 105: 977-81.
22. Queenan J Jr, Kao LC, Arboleda CE, Ulloa-Aguirre A, Golos TG, Cines DB. Strauss J3. Regulation of urokinase-type plasminogen activator production by cultured human cytotrophoblasts. J Biol Chem 1987; 262: 10903-6.
23. Mira-y-Lopez R. Retinoic acid priming potentiates the induction of urokinase-type plasminogen activator by cyclic adenosine monophosphate in mouse mammary carcinoma cells. J Cell Physiol 1991; 147: 46-54.
24. Takeuchi T, Niiya K, Kubonishi I, Miyoshi I. A plasminogen activator inhibitor-2 from a promyelocytic leukemia cell line, PL-21, binds to the carboxy-terminal chain of plasminogen activators. Thromb Haemost 1990; 63: 259-64.
25. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
26. Pearson D, Nigg EA, Nagamine Y, Jans DA, Hemmings BA. Mechanisms of cAMP-mediated gene induction: examination of renal epithelial cell mutants affected in the catalytic subunit of the cAMP-dependent protein kinase. Exp Cell Res 1991; 192: 315-8.
27. Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-34.
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
29. Sambrook J, Fritsh EF, Maniatis T. Molecular Cloning, A Laboratory Manual 2nd Ed. (2nd Ed. ed.) Cold Spring Harter Laboratory, 1989: p 7.39.
30. White WF, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966; 5: 2160-9.
31. Jans DA, Hemmings BA. LLC-PK1 cell mutants in cAMP metabolism respond normally to phorbol esters. FEBS Lett 1986; 205: 127-31.
32. Rondeau E, Ochi S, Lacave R, He CJ, Medcalf R. Delarue F, Sraer JD. Urokinase synthesis and binding by glomerular epithelial cells in culture. Kidney Int 1989; 36: 593-600.
33. Medcalf RL. Cell- and gene-specific interactions between signal transduction pathways revealed by okadaic acid. Studies on the plasminogen activating system. J Biol Chem 1992; 267: 12220-6.
34. von der Ahe D, Pearson D, Nagamine Y. Macromolecular interaction on a cAMP responsive region in the urokinase-type plasminogen activator gene: a role of protein phosphorylation. Nucleic Acids Res 1990; 18: 1991-9.
35. Ziegler A, Knesel J, Fabbro D, Nagamine Y, Protein kinase C down-regulation enhances cAMP-mediated induction of urokinase-type plasminogen activator mRNA in LLC-PK1 cells. J Biol Chem 1991; 266: 21067-74.
36. Foulkes NS, Borrelli E, Sassone-Corsi P. CREM gene: use of alternative DNA-binding domains generates multiple antagonists of cAMP-induced transcription. Cell 1991; 64: 739-49.
37. Hayashi T, Niiya K, Hirokawa S, Sakuragawa N. Synergistic stimulating effect between cyclic AMP and phorbol ester on plasminogen activator inhibitor type 2 production in human promyelocytic leukemia cell line PL-21. Biochim Biophys Acta 1992; 1134: 273-7.
38. Niiya K, Taniguchi T, Shinbo M, Ishikawa T, Tazawa S, Hayakawa Y, Sakuragawa N. Different regulation of plasminogen activator inhibitor 2 gene expression by phorbol ester and cAMP in human myeloid leukemia cell line PL-21. Thromb Haemost 1994; 72: 92-7.